Royalty Pharma (RPRX) Operating Expenses (2019 - 2026)

Royalty Pharma has disclosed Operating Expenses across 8 years of filings, most recently posting $541.0 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 46.67% year-over-year to $541.0 million; the TTM figure through Jun 2026 stood at $1.0 billion (up 120.43% YoY), while the FY2025 annual figure was $818.7 million, down 15.7% from the prior year.
• Operating Expenses came in at $541.0 million for Q2 2026 at Royalty Pharma, up from $67.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.0 billion in Q4 2022 to a low of -$170.4 million in Q3 2024.
• Average Operating Expenses over 5 years is $288.4 million, with a median of $250.6 million recorded in 2024.
• The largest YoY upside for Operating Expenses was 1479.41% in 2024 against a maximum downside of 144.27% in 2024.
• Over 5 years, Operating Expenses stood at $1.0 billion in 2022, then sank by 101.61% to -$16.8 million in 2023, then jumped by 1479.41% to $232.1 million in 2024, then climbed by 0.64% to $233.6 million in 2025, then soared by 131.59% to $541.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $541.0 million in Q2 2026, $67.5 million in Q1 2026, and $233.6 million in Q4 2025.